.After a handful of years in biotech, Mike Quigley, Ph.D., is actually returning to the pharma layer, using up the best scientific research area at Sanofi.Quigley will definitely begin Sept. 30 as the French Big Pharma's primary clinical officer as well as international chief of research study, Sanofi told Fierce Biotech in an emailed statement.Quigley is actually replacing Frank Nestle, M.D., that left behind Sanofi this spring among an international overhaul of the provider's R&D unit. Nestle, who invested 8 years along with the pharma, jumped over to Deerfield Monitoring, where he currently serves as a partner on the rehabs team and also chief executive officer of the firm's curative revelation and also advancement procedures.
Quigley is going to sign up with Sanofi from a San Francisco-based biotech that remains in stealth, according to his LinkedIn profile page. He's presently noted as the business's co-founder, head of state as well as chief executive officer.Since August 2021, Quigley has actually worked as a project companion at SV Health and wellness Investors, a healthcare fund manager along with current expenditures in biotechs such as BioAge, Cerevance, Dualitas Rehabs and also Nimbus Rehabs, to name a few. Quigley in the past held the top location at Dualitas, a biotech that stays in secrecy, depending on to STAT.The prospective Sanofi forerunner additionally earlier helmed Therini Bio, an immunotherapy biotech functioning to create procedures for neurodegenerative health conditions driven through general problems.Just before devoting the last couple of years in biotech, Quigley has an even longer record in Major Pharma, most recently serving as Gilead's senior vice head of state of research biology up until the summertime of 2021. Before that, he clocked in much more than four years around several management tasks at Bristol Myers Squibb as well as functioned as a medical supervisor at Johnson & Johnson's Janssen upper arm prior to that.Sanofi pointed out Quigley's objective in his brand-new job would certainly be to "maximize our chance of excellence with ideal partnerships throughout our organization as well as past, bringing best-in-class advancement as well as creating and sourcing new industry-leading skill with a devotion to diversity," depending on to an internal memo acquired through STAT.